申请人:Arysta LifeScience Corporation
公开号:US20160237047A1
公开(公告)日:2016-08-18
The disclosure includes a process for preparing fluoxostrobin which includes:
(i) reacting benzofuran-3(2H)-one O-methyl oxime (10) with an alkyl nitrite in the presence of an acid to form (3E)-2,3-benzofuran-dione O
3
-methyl dioxime (11A) as a predominant isomer;
(ii) reacting (3E)-2,3-benzofuran-dione O
3
-methyl dioxime (11A) with 2-haloethanol to form (3E)-benzofuran-2,3-dione O
2
-(2-hydroxyethyl) O
3
-methyl dioxime (12A); and
(iii) reacting (3E)-benzofuran-2,3-dione O
2
-(2-hydroxyethyl) O
3
-methyl dioxime (12A) with a base to form (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (13)
(iv) reacting a 4,6-di-halo-5-fluoro-pyrimidine (5), wherein X
1
is halogen, with (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime (13), in the presence of a solvent and optionally in the presence of a base, to form an (E)-(2-((6-halo-5-fluoropyrimidin-4-yl)oxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyl oxime (14):
(v) reacting the (E)-(2-((6-halo-5-fluoropyrimidin-4-yl)oxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyl oxime (
14
) with 2-chlorophenol, in the presence of a solvent and optionally in the presence of a base, to form fluoxastrobin:
该披露涉及一种制备氟吡菌酯的过程,包括:(i) 在酸的存在下,将苯并呋喃-3(2H)-酮O-甲基肟(10)与烷基亚硝酸盐反应,形成(3E)-2,3-苯并呋喃二酮O3-甲基二肟(11A)作为主要异构体;(ii) 将(3E)-2,3-苯并呋喃二酮O3-甲基二肟(11A)与2-卤代乙醇反应,形成(3E)-苯并呋喃-2,3-二酮O2-(2-羟乙基)O3-甲基二肟(12A);(iii) 将(3E)-苯并呋喃-2,3-二酮O2-(2-羟乙基)O3-甲基二肟(12A)与碱反应,形成(E)-(5,6-二氢-1,4,2-二噁嗪-3-基)(2-羟基苯基)甲酮O-甲基肟(13);(iv) 在溶剂的存在下,可选地在碱的存在下,将4,6-二卤-5-氟嘧啶(5),其中X1为卤素,与(E)-(5,6-二氢-1,4,2-二噁嗪-3-基)(2-羟基苯基)甲酮O-甲基肟(13)反应,形成(E)-(2-((6-卤代-5-氟嘧啶-4-基)氧基)苯基)(5,6-二氢-1,4,2-二噁嗪-3-基)甲酮O-甲基肟(14);(v) 在溶剂的存在下,可选地在碱的存在下,将(E)-(2-((6-卤代-5-氟嘧啶-4-基)氧基)苯基)(5,6-二氢-1,4,2-二噁嗪-3-基)甲酮O-甲基肟(14)与2-氯苯酚反应,形成氟吡菌酯。